PLB1 Antibody

What is PLB1 and why is it significant in research?

PLB1 (phospholipase B1) is a phospholipase enzyme encoded by the PLB1 gene (Gene ID: 151056) that has emerged as a significant research target across several fields including microbiology, immunology, and cancer research . PLB1 has been implicated in the virulence mechanism of pathogenic fungi such as Candida albicans, where it enhances the organism's ability to cross the gastrointestinal tract and disseminate hematogenously . Additionally, recent genetic studies have identified PLB1 as a candidate risk gene for rheumatoid arthritis (RA), with evidence suggesting that rare, low-frequency, and common alleles at the PLB1 locus might contribute to disease risk . The protein's observed molecular weight is approximately 45 kDa, and it functions in multiple biological processes that make it a valuable target for both basic research and potential therapeutic applications .

What applications are PLB1 antibodies typically used for?

PLB1 antibodies are utilized across multiple research applications, with the most common being:

PLB1 antibodies have been successfully tested in human samples, particularly in prostate cancer cell lines such as DU 145 cells for Western blot applications, and in human prostate hyperplasia tissue for immunohistochemistry . In specialized applications, anti-PLB1 antibodies have been employed in immunofluorescence and immunoelectron microscopic studies to visualize PLB1 secretion during tissue invasion by pathogenic organisms like Candida albicans . The appropriate application and dilution should be determined through titration experiments for each specific research context.

How should PLB1 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of PLB1 antibodies is critical for maintaining their specificity and activity. Based on standard protocols for antibody 26835-1-AP:

• Store at -20°C, where the antibody remains stable for one year after shipment

• The antibody is provided in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is generally unnecessary for -20°C storage, reducing the risk of contamination from multiple freeze-thaw cycles

• For small volume formats (20μl), the solution contains 0.1% BSA as a stabilizer

• When working with the antibody, maintain cold chain practices by keeping the antibody on ice during experiments

• Avoid repeated freeze-thaw cycles which can degrade antibody performance

• Use sterile technique when handling to prevent microbial contamination

For long-term projects requiring consistent antibody performance, validation of each new lot against a reference standard is recommended to ensure reproducibility across experiments.

What controls should be included when using PLB1 antibodies?

When designing experiments using PLB1 antibodies, appropriate controls are essential for result validation and troubleshooting:

• Positive controls: Include samples known to express PLB1, such as DU 145 cells for Western blot applications or human prostate hyperplasia tissue for IHC .

• Negative controls:

  • Isotype control: Use a non-specific antibody of the same isotype (Rabbit IgG for PLB1 antibody 26835-1-AP) to assess non-specific binding .

  • Secondary antibody-only control: Omit the primary antibody to detect non-specific binding of the secondary antibody.

  • Antigen competition assay: Pre-incubate the antibody with purified PLB1 protein to demonstrate binding specificity.

• Genetic controls: When possible, include samples with PLB1 gene knockout or knockdown to confirm antibody specificity. In microbial studies, comparing PLB1 null mutants with wild-type and revertant strains provides rigorous validation of antibody specificity, as demonstrated in C. albicans virulence studies .

• Tissue/cell type controls: Include samples from multiple tissues/cell types with varying PLB1 expression levels to demonstrate detection range.

Systematic inclusion of these controls allows for confident interpretation of experimental results and troubleshooting of unexpected findings.

How can PLB1 antibodies be used to study pathogen virulence mechanisms?

PLB1 antibodies have proven instrumental in elucidating virulence mechanisms of pathogenic organisms, particularly in fungal pathogens like Candida albicans. Researchers can employ these antibodies through multiple advanced approaches:

• Localization studies during host invasion: Immunofluorescence and immunoelectron microscopy using anti-PLB1 antibodies can visualize PLB1 secretion during tissue invasion. This approach has demonstrated that PLB1 is actively secreted during Candida albicans invasion of the gastric mucosa, with significantly stronger labeling observed in parental and revertant strains compared to null mutants .

• Host-pathogen interaction studies: PLB1 antibodies can help identify host cellular structures targeted by pathogen phospholipases during invasion processes.

• Quantitative assessment of PLB1 expression: Western blot and ELISA using PLB1 antibodies can measure changes in PLB1 expression under different environmental conditions, stress responses, or in different mutant backgrounds.

• Virulence model validation: Using PLB1 antibodies in animal models of infection allows researchers to correlate PLB1 expression with virulence outcomes, as demonstrated in both intravenous and oral-intragastric mouse models of candidiasis .

These approaches can be integrated with genetic studies comparing wild-type strains, PLB1 null mutants, and revertant strains to definitively establish the role of PLB1 in virulence, transmission, and tissue invasion processes.

What methodological considerations are important when using PLB1 antibodies for immunohistochemistry?

Successful immunohistochemistry (IHC) with PLB1 antibodies requires attention to several technical aspects:

Each of these parameters should be systematically optimized to achieve consistent and specific PLB1 detection in tissue samples.

How can PLB1 antibodies be adapted for advanced imaging applications?

PLB1 antibodies can be modified and incorporated into various advanced imaging techniques:

• Conjugation strategies for direct detection: While the standard PLB1 antibody (26835-1-AP) is provided in unconjugated form , direct conjugation to fluorophores, enzymes, or nanoparticles can enhance detection sensitivity and simplify protocols by eliminating secondary antibody steps.

• Super-resolution microscopy applications: PLB1 antibodies can be adapted for techniques such as STORM, PALM, or STED microscopy by conjugation to appropriate photo-switchable fluorophores, enabling visualization of PLB1 distribution at nanometer resolution.

• In vivo imaging approaches: Drawing from approaches used with other antibodies, such as the anti-TIP1 antibody, PLB1 antibodies could potentially be labeled with positron emitters like [89Zr]Zr using deferoxamine (DFO) chelator for PET imaging applications . This approach would require optimization of:

  • DFO-to-antibody ratio (with 1:1 showing improved tumor binding compared to 3:1 in some applications)

  • Radiochemical purity (>99% is achievable with optimized protocols)

  • Stability in human serum (assessment over 7+ days is recommended)

  • Immunoreactive fraction (>95% is desirable)

• Multimodal imaging: PLB1 antibodies can be dual-labeled for both optical imaging and PET/SPECT applications, allowing correlation between microscopic and whole-body distribution.

Adaptation of PLB1 antibodies for these advanced applications requires careful validation to ensure that conjugation or modification does not compromise binding specificity or affinity.

What approaches can be used to validate PLB1 antibody specificity?

Rigorous validation of PLB1 antibody specificity is essential for reliable research outcomes. Multiple complementary approaches should be employed:

• Genetic validation:

  • Use of PLB1 knockout or knockdown models to confirm absence of signal

  • Testing in revertant strains to demonstrate restoration of detection, as demonstrated in C. albicans studies where PLB1 null mutants showed little to no labeling while parental and revertant strains exhibited strong signal

• Biochemical validation:

  • Western blot analysis confirming detection at the expected molecular weight (45 kDa for PLB1)

  • Immunoprecipitation followed by mass spectrometry identification

  • Pre-absorption controls using recombinant PLB1 protein

• Advanced analytical techniques:

  • Surface plasmon resonance (SPR) to determine binding kinetics and affinity, similar to methods used for other antibodies

  • Epitope mapping using overlapping peptides

  • In silico analysis of antibody-antigen interaction using molecular docking tools like Schrödinger's Biologics Suite

• Cross-reactivity assessment:

  • Testing against related phospholipases to ensure specificity

  • Evaluation in multiple species if cross-reactivity is claimed

• Orthogonal detection methods:

  • Correlation with mRNA expression data

  • Comparison with alternative antibody clones targeting different epitopes

These validation approaches should be systematically documented and reported to establish confidence in experimental findings using PLB1 antibodies.

How should quantitative data from PLB1 antibody-based experiments be analyzed?

Quantitative analysis of PLB1 antibody data requires appropriate statistical approaches depending on the experimental method:

• Western blot densitometry:

  • Normalize PLB1 band intensity to loading controls (β-actin, GAPDH, etc.)

  • Use technical replicates (minimum n=3) and biological replicates

  • Apply appropriate statistical tests based on data distribution (t-test for normal distribution, non-parametric tests for non-normal)

  • Report fold-change with error bars representing standard deviation or standard error

• Immunohistochemistry quantification:

  • Define objective scoring criteria (H-score, percentage positive cells, intensity scales)

  • Use digital image analysis software when possible to reduce subjective bias

  • Assess multiple fields per sample (minimum 5-10 randomly selected fields)

  • Account for regional heterogeneity in expression

  • Consider blinded scoring by multiple observers

• Flow cytometry analysis:

  • Report median fluorescence intensity (MFI) rather than mean when appropriate

  • Set gates based on appropriate controls (isotype, fluorescence-minus-one)

  • Use compensation controls when multiplexing

  • Apply appropriate transformations for visualization (biexponential for flow data)

• ELISA and other quantitative assays:

  • Generate standard curves with appropriate range (r²>0.98)

  • Include quality control samples with known values

  • Assess intra- and inter-assay variability (%CV)

  • Determine limit of detection and quantification

• Statistical reporting standards:

  • Clearly state statistical tests used

  • Report exact p-values rather than thresholds

  • Control for multiple comparisons when appropriate

  • Consider power analysis for sample size determination

Adhering to these analytical approaches ensures robust and reproducible quantification of PLB1 expression or activity across experimental systems.

How can PLB1 antibodies be used in multiplexed detection systems?

Multiplexed detection incorporating PLB1 antibodies enables simultaneous analysis of PLB1 with other markers, providing richer contextual data:

• Immunofluorescence multiplexing strategies:

  • Traditional multiplexing using distinct fluorophores on separate antibodies

  • Spectral imaging to resolve overlapping fluorescence spectra

  • Sequential detection using antibody stripping/reprobing

  • Tyramide signal amplification for detecting low-abundance targets alongside PLB1

  • Considerations for PLB1 antibody (26835-1-AP): Being a rabbit polyclonal, it should be paired with antibodies from different host species (mouse, goat, etc.) to avoid cross-reactivity with secondary antibodies

• Mass cytometry/imaging mass cytometry:

  • Metal-conjugated PLB1 antibodies for highly multiplexed analysis

  • Spatial resolution of PLB1 with >30 additional markers

  • Elimination of spectral overlap concerns

• Multiplex IHC platforms:

  • Automated sequential staining/scanning systems

  • Multispectral imaging analysis

  • Computational tissue phenotyping incorporating PLB1 expression

• Proximity-based detection methods:

  • Proximity ligation assay (PLA) to detect PLB1 interactions with potential binding partners

  • CODEX or IBEX for highly multiplexed tissue imaging including PLB1

• Practical considerations for multiplexing:

  • Optimize individual staining protocols before combining

  • Include appropriate controls for each marker

  • Account for potential antibody cross-reactivity

  • Consider order of antibody application for sequential methods

  • Validate multiplex results against single-plex standards

These multiplexed approaches provide systems-level insights into PLB1 biology within its broader cellular and tissue context.

What are the potential pitfalls in PLB1 antibody-based research and how can they be addressed?

Researchers should be aware of several potential challenges when working with PLB1 antibodies:

• Cross-reactivity concerns:

  • Phospholipases share conserved domains that may lead to antibody cross-reactivity

  • Solution: Validate specificity using PLB1 knockout models; perform thorough control experiments including pre-absorption with recombinant PLB1

• Batch variability:

  • Polyclonal antibodies like 26835-1-AP may show batch-to-batch variation

  • Solution: Maintain reference standards for validation of new lots; consider pooling antibody batches for long-term studies

• Epitope masking:

  • Fixation methods may mask PLB1 epitopes

  • Solution: Optimize antigen retrieval methods (TE buffer pH 9.0 is recommended, with citrate buffer pH 6.0 as an alternative)

• Background in specific tissues:

  • Endogenous peroxidase or biotin can cause high background in IHC

  • Solution: Include appropriate blocking steps; optimize antibody concentration; consider alternative detection systems

• Quantification challenges:

  • Subjective interpretation of staining intensity

  • Solution: Use digital image analysis; blind observers; establish clear scoring criteria

• Conflicting results between applications:

  • Antibody may perform differently in WB versus IHC

  • Solution: Application-specific validation; consider using multiple antibodies targeting different epitopes

• Low signal in specific applications:

  • Some applications may require signal amplification

  • Solution: Consider tyramide signal amplification or other enhancing methods; optimize antibody concentration for each application

• Reproducibility concerns:

  • Protocol variations between labs

  • Solution: Detailed protocol sharing; standardization efforts; proper reporting of all experimental parameters

• Non-specific binding in particular cell types:

  • Fc receptor-mediated binding

  • Solution: Use appropriate Fc blocking reagents; validate using Fab fragments

• Limited species cross-reactivity:

  • The currently available antibody is tested primarily with human samples

  • Solution: Validate cross-reactivity with target species; consider species-specific antibodies for non-human studies

Awareness of these potential pitfalls and implementation of appropriate solutions ensures more reliable and reproducible PLB1 antibody-based research.

How might PLB1 antibodies be utilized in rheumatoid arthritis research?

Recent genetic studies have implicated PLB1 as a candidate risk gene for rheumatoid arthritis (RA), suggesting several potential research applications for PLB1 antibodies in this field:

• Expression studies in RA tissues:

  • Immunohistochemical analysis of PLB1 expression in synovial tissue from RA patients versus controls

  • Correlation of PLB1 expression levels with disease severity, progression, or treatment response

  • Dual staining with immune cell markers to identify cellular sources of PLB1 in RA synovium

• Genetic-phenotypic correlation studies:

  • Analysis of PLB1 protein expression in patients carrying different PLB1 genetic variants (common, low-frequency, and rare variants) identified in genetic studies

  • Investigation of whether specific variants (such as the non-synonymous c.2263G>C (p.G755R) mutation) alter PLB1 protein expression, localization, or function

  • Correlation of PLB1 expression with other RA biomarkers

• Functional studies:

  • Using PLB1 antibodies to neutralize or modulate PLB1 function in ex vivo models

  • Immunoprecipitation studies to identify PLB1 interaction partners in RA-relevant cell types

  • Phospholipase activity assays in conjunction with PLB1 antibody-based detection

• Biomarker development:

  • Evaluation of PLB1 as a potential diagnostic or prognostic biomarker in RA

  • Development of standardized ELISA protocols for PLB1 quantification in patient samples

  • Longitudinal studies of PLB1 expression during disease progression or treatment

• Therapeutic targeting studies:

  • Investigation of PLB1 antibodies as potential therapeutic agents

  • Monitoring PLB1 expression changes in response to current RA therapies

  • Developing targeted approaches to modulate PLB1 expression or activity

These applications could help elucidate the role of PLB1 in RA pathogenesis and potentially identify new therapeutic targets or biomarkers.

How can PLB1 antibodies be adapted for therapeutic applications?

While current PLB1 antibodies are primarily research tools, their adaptation for therapeutic applications would involve several developmental considerations:

• Humanization and optimization:

  • Current research antibodies like 26835-1-AP (rabbit polyclonal) would need to be humanized to reduce immunogenicity

  • Conversion to monoclonal format for consistency

  • Affinity maturation to enhance binding properties

  • Fc engineering to optimize effector functions based on therapeutic goals

• Functional screening:

  • Assessment of neutralizing capacity against PLB1 enzymatic activity

  • Evaluation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) if target cell deletion is desired

  • Testing for unintended agonist activity

• Conjugation strategies:

  • Potential development as antibody-drug conjugates for targeted delivery

  • Radiolabeling for theranostic applications, drawing from approaches used with other antibodies like anti-TIP1

  • Bispecific formats to engage immune cells or target multiple pathways

• Advanced characterization:

  • Surface plasmon resonance (SPR) for affinity determination

  • In silico immunogenicity risk assessment similar to methods used for other therapeutic antibodies

  • Epitope mapping to ensure targeting of functionally relevant domains

  • Cross-reactivity profiling against related phospholipases

• Delivery and formulation:

  • Stability optimization for extended shelf-life

  • Formulation development for appropriate administration route

  • Pharmacokinetic studies to determine dosing schedules

• Therapeutic contexts:

  • For infectious diseases: Development of anti-PLB1 antibodies targeting pathogen-specific PLB1 variants, such as those in Candida albicans

  • For autoimmune conditions: Modulating PLB1 activity in conditions like rheumatoid arthritis where PLB1 genetic variants have been implicated

  • For cancers: Targeting PLB1-expressing malignant cells, potentially using approaches similar to those employed with other targeted antibodies

Adaptation of research-grade PLB1 antibodies for therapeutic applications represents a significant but potentially valuable developmental pathway.

What are the optimized protocols for Western blot detection of PLB1?

The following protocol is optimized for Western blot detection of PLB1, based on standard practices and specific recommendations for antibody 26835-1-AP:

Sample Preparation:

• Lyse cells or tissues in RIPA buffer containing protease inhibitors

• Determine protein concentration using BCA or Bradford assay

• Prepare samples at 20-50 μg total protein per lane

• Mix with Laemmli buffer containing reducing agent and heat at 95°C for 5 minutes

Gel Electrophoresis and Transfer:

• Resolve proteins on 10-12% SDS-PAGE (suitable for detecting 45 kDa PLB1)

• Transfer to PVDF membrane (0.45 μm) using semi-dry or wet transfer systems

• Verify transfer efficiency using reversible protein staining (Ponceau S)

Immunodetection:

• Block membrane in 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary PLB1 antibody (26835-1-AP) at dilution of 1:500-1:2000 in blocking buffer overnight at 4°C

• Wash 3x with TBST, 5 minutes each

• Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000) for 1 hour at room temperature

• Wash 3x with TBST, 5 minutes each

• Develop using ECL substrate and image using appropriate detection system

Expected Results:

• PLB1 should be detected at approximately 45 kDa

• Positive control: DU 145 cells have been verified to express detectable PLB1

Troubleshooting Tips:

• No signal: Increase antibody concentration; extend exposure time; verify transfer efficiency

• High background: Increase blocking time; reduce antibody concentration; increase wash duration

• Multiple bands: Validate specificity with blocking peptide; optimize sample preparation to prevent degradation

• Unexpected molecular weight: Verify with positive control; consider post-translational modifications

This protocol can be adapted based on specific laboratory equipment and sample types.

What methods can be used to quantify PLB1 expression or activity in biological samples?

Several complementary approaches can be used to quantify PLB1 at the protein expression or activity level:

Protein Expression Quantification:

• Western Blot Densitometry:

  • Detect PLB1 using optimized protocols with antibody 26835-1-AP

  • Normalize to loading controls (β-actin, GAPDH)

  • Quantify band intensity using image analysis software

  • Suitable for relative quantification between samples

• ELISA-based Quantification:

  • Develop sandwich ELISA using capture and detection antibodies against different PLB1 epitopes

  • Generate standard curve using recombinant PLB1

  • Suitable for absolute quantification in solution-phase samples

  • Can be adapted for high-throughput screening

• Flow Cytometry:

  • For cellular expression analysis in suspension cells

  • Requires cell permeabilization for intracellular PLB1 detection

  • Provides single-cell resolution data on expression levels

  • Allows correlation with other cellular markers

• Mass Spectrometry:

  • Targeted proteomics approaches using selected/multiple reaction monitoring (SRM/MRM)

  • Absolute quantification using isotope-labeled standards

  • Provides high specificity and sensitivity

  • Can simultaneously detect post-translational modifications

Enzymatic Activity Quantification:

• Phospholipase Activity Assays:

  • Fluorogenic substrate assays measuring PLB1 enzymatic activity

  • Radiometric assays using labeled phospholipid substrates

  • Colorimetric assays measuring released products

  • Activity can be correlated with protein expression using PLB1 antibodies

• Cell-based Functional Assays:

  • Measure physiological outcomes of PLB1 activity

  • Couple with PLB1 antibody neutralization to confirm specificity

  • Examples include membrane permeability or lipid remodeling assays

These methodologies can be selected based on specific research questions, available sample types, and required sensitivity/specificity parameters.

How might emerging technologies enhance PLB1 antibody applications?

Several cutting-edge technologies are poised to expand the utility of PLB1 antibodies in research and clinical applications:

• Single-cell proteomics integration:

  • Combining PLB1 antibody detection with single-cell RNA sequencing for multi-omic analysis

  • Single-cell protein analysis using platforms like CITE-seq or REAP-seq

  • Correlation of PLB1 protein expression with transcriptomic profiles at single-cell resolution

• Advanced imaging technologies:

  • Expansion microscopy for sub-diffraction imaging of PLB1 localization

  • Lattice light-sheet microscopy for dynamic PLB1 visualization in living cells

  • Cryo-electron tomography with immunogold-labeled PLB1 antibodies for ultrastructural localization

• Protein-protein interaction mapping:

  • Proximity labeling approaches (BioID, APEX) coupled with PLB1 antibodies for isolation and identification of interaction partners

  • Advanced co-immunoprecipitation techniques with crosslinking for capturing transient interactions

  • Förster resonance energy transfer (FRET) analysis for real-time interaction studies

• Targeted protein degradation applications:

  • Development of PLB1-targeting proteolysis-targeting chimeras (PROTACs)

  • Antibody-based degrader conjugates targeting PLB1 for selective degradation

  • Monitoring degradation kinetics using quantitative PLB1 antibody detection

• Spatial transcriptomics integration:

  • Combining PLB1 antibody detection with spatial transcriptomics for correlation of protein expression with local transcriptional landscapes

  • In situ sequencing approaches with protein detection

  • Digital spatial profiling incorporating PLB1 antibodies

• Artificial intelligence applications:

  • AI-powered image analysis for automated quantification of PLB1 expression in complex tissues

  • Machine learning approaches to identify novel patterns in PLB1 distribution or expression

  • Predictive modeling of PLB1 involvement in disease processes based on integrated data

These emerging technologies promise to enhance the specificity, sensitivity, and contextual information obtained from PLB1 antibody-based studies, driving new discoveries in PLB1 biology and potential therapeutic applications.